Table 2.

Registered clinical trials relating to traditional Chinese medicine prescriptions containing baicalein (active ingredient of Huangqin) for treatment of COVID-19 patients (Chinese Clinical Trial Registry, www.chictr.org/cn/ (accessed on 31 January 2021).

Baicalein (The Active Ingredient of Huangqin)	Molecular Mechanisms of Baicalein	Herbal Formula Containing Huangqin	Registration Number	Sample Size of the Control Group
	RdRp inhibitor via noncovalent incorporation [73], potent antagonists against TMPRSS2 [70], improving respiratory function, decreasing IL-1β and TNF-α levels, and inhibiting cell infiltration [71,72].	Qingfei Paidu decoction	ChiCTR2000029433	120
			ChiCTR2000030883	100
			ChiCTR2000032767	782
		Xinguan I decoction	ChiCTR2000029637	50
		Tanreqing capsules	ChiCTR2000029813	36
		Tanreqing injection	ChiCTR2000029432	72
		Kegan Liyan oral liquid	ChiCTR2000033720	240
			ChiCTR2000033745	240
			ChiCTR2000031982	240
		Shuanghuanglian oral liquid	ChiCTR2000033133	30
			ChiCTR2000029605	100
		Toujie Quwen granule	ChiCTR2000031888	150